statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Accumulate Zydus Lifesciences; target of Rs 1186: KR Choksey

KR Choksey recommended accumulate rating on Zydus Lifesciences with a target price of Rs 1186 in its research report dated May 21, 2024.

Buy Zydus Lifesciences; target of Rs 1200: Sharekhan

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1200 in its research report dated May 18, 2024.

Stock Radar: JSW Steel, Zydus Life, Bandhan Bank, Zee Entertainment in focus today

Anupam Rasayan India, ASK Automotive, Chemcon Speciality Chemicals, Data Patterns (India), Gujarat Ambuja Exports, Jyoti CNC Automation, Trident, and Ujjivan Small Finance Bank will release March quarter earnings on May 18.

Trade Spotlight | How to trade in Zydus Lifesciences, Hind Copper and Siemens today

Siemens ended at new closing high of Rs 5,768, and formed long bullish candlestick pattern on the daily timeframe, while the trading volumes in last three sessions remained healthy.

Zydus Life gains over 3% on launch of bladder control drug

Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period

Steady US sales to bring a healthy quarter for pharma sector

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Zydus Lifesciences up marginally despite 4 observations from USFDA

USFDA inspected Zydus Lifesciences' Onco injectable manufacturing plant in Ahmedabad from March 18 to 27

US FDA issues 4 observations for Zydus Life's Ahmedabad injectable plant

Earlier on 26 March, Zydus Life's shares surged after the company received tentative approval from the US Food and Drug Administration (FDA) for its Letermovir tablets.

Buy Zydus Lifesciences; target of Rs 1100: Sharekhan

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated March 20, 2024.

Zydus Lifesciences rises 2% on launch of cancer drug Olaparib

The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach.

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Volume	1.35M
52-Wk High	1,210.00
52-Wk Low	567.75

ZYDUSLIFE.NSE Zydus Lifesciences Ltd.

About

Feed

News

Sentiment

Fundamentals